摘要
Abstract
Objective A comparative study was conducted of the clinical efficacy between ticagrelor and clopidogrel in patients of acute coronary syndrome with type 2 diabetes mellitus after percutaneous coronary intervention (PCI).Methods In our hospital,115 patients with diabetic syndrome who had undergone acute coronary surgery in the treatment of coronary intervention,were divided into ticagrelor (n=52) and clopidogrel (n=63) group.The group for ticagrelor was treated with 300 mg ticagrel and 180 mg aspirin preoperatively,and 90 mg ticagrelor postoperatively,2 times/day;the group for clopidogrel received the loading dose of clopidogrel aspirin for 300 mg before surgery,75 mg for clopidogrel and aspirin for 100 mg after surgery,1 time/day to maintain.All patients received intravenous blood collection before and after PCI two months later and four months later.The platelet function indexes P-selection of platelet (CD62P),CD63 and Maximum Platelet Aggregation Rate (MPAR) were measured.Adverse cardiovascular events and complications were observed and compared between the two groups in the course of medication for 6 months.Results There was no significant difference between the two groups in preoperative baseline data,blood glucose level and other indicators of PCI and there was no significant difference in platelet function index (CD62P/CD63 and MPAR) before the operation of PCI.After PCI double anticoagulant therapy for two months,the platelet function index (CD62P/CD63 and MPAR) for the two groups were significantly decreased compared with that before treatment.After four month's treatment as above,the numerical index of platelet function continued to decline,and the difference was statistically significant between the two groups (P ＜ 0.05).And six months after the operation,the incidence of major adverse cardiovascular events of the ticagrelor group was lower than that of the clopidogrel group,showing statistical significance in the difference between the groups (P ＜0.05).Conclusion For acute coronary syndrome patients with type 2 diabetes mellitus patients after PCI,ticagrelor combined with aspirin double anticoagulant therapy could effectively inhibit platelet function and reduce platelet aggregation rate.After 6 month,major adverse cardiovascular events rate could be lowered and the risk of bleeding reduced.关键词
急性冠状动脉综合征/2型糖尿病/经皮冠状动脉介入/替格瑞洛/氯吡格雷Key words
acute coronary syndrome/type 2 diabetes mellitus/percutaneous coronary intervention/ticagrelor/clopidolgrel分类
医药卫生
